SOST

SOST Informations sur la molécule

Nom anglaisSclerostinNombre de médicaments commercialisés1
Nombre de médicaments cliniques6Alias de la cibleSclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Phase de R&D la plus avancéeApproved
Nom anglaisSclerostin
Alias de la cibleSclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques6
Phase de R&D la plus avancéeApproved

SOST Liste de produits

  • Attribut

    Protein (4)

  • Bibliothèque de produits

    En ligne (4)

  • Espèces

    Human (2)Mouse (2)

  • Étiquette

    His Tag (3)His Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (2)Biotin-labeled (2)

SOSTContexte de la molécule

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOSTAlias de la molécule

SOST,VBCH

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
SetrusumabUX143; NOV-3; MOR-05813; BPS-804Phase 3 ClinicalMorphosys Ag, Novartis Pharma AgBone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic
Details
AGA-2115AGA2115; AGA-2115Phase 2 ClinicalAngitia Biopharmaceuticals (Guangzhou) LtdOsteogenesis Imperfecta
Details
AGA-2118AGA-2118Phase 2 ClinicalAngitia Biomedicines LtdOsteoporosis; Osteoporosis, Postmenopausal
Details
ResugosbartSHR-1222Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co LtdOsteoporosis; Osteoporosis, Postmenopausal
Details
Romosozumab biosimilar(Zhuhai Federation Biomedicine)Phase 1 ClinicalZhuhai Federation Biomedicine Co LtdOsteoporosis, Postmenopausal
Details
BlosozumabTST002; LY-2541546; TST002-IgG4Phase 1 ClinicalEli Lilly And CompanyOsteoporosis; Osteoporosis, Postmenopausal
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
RomosozumabCDP-7851; AMG-785ApprovedEvenity, EVENITYJapanOsteoporosisAmgen Inc2019-01-08Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques